|
| 白蛋白结合型紫杉醇用于晚期乳腺癌的有效性及安全性观察 |
| Effect of Albumin-bound Paclitaxel on the efficacy of patients with advanced breast cancer |
| 投稿时间：2024-11-24 修订日期：2024-11-28 |
| DOI： |
|
 |
| 中文关键词: 白蛋白结合型紫杉醇 晚期 乳腺癌 临床疗效 生活质量 不良反应 |
| 英文关键词:Albumin-bound paclitaxel Advanced Breast cancer Clinical efficacy Quality of life Adverse effects |
| 基金项目: |
|
| 摘要点击次数: 33 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【】? 目的? 观察和探讨晚期乳腺癌采用白蛋白结合型紫杉醇的近期疗效及安全性。方法? 随机选取2019年1月至2023年10月于东阳市中医院接受治疗的晚期乳腺癌患者80例为研究对象,分为对照组(n=40)和观察组(n=40)。对照组患者单独使用多西他赛治疗,观察组单独使用白蛋白结合型紫杉醇治疗。比较两组患者治疗前后的客观缓解率(ORR)、肿瘤标志物水平(癌胚抗原(CEA)、糖类抗原153(CA153))、不良反应发生率。结果? 治疗后,观察组和治疗组的客观缓解率(ORR)分别为80.0％和55.0％,差异有统计学意义(P＜0.05)。治疗后观察组癌胚抗原(CEA)、糖类抗原153(CA153)水平低于对照组(P＜0.05)。观察组的不良反应总发生率显著低于对照组(χ2 =4.857,P＜0.05),但是观察组的神经毒性发生率高于对照组(χ2 =4.713,P＜0.05)。结论? 采用白蛋白结合型紫杉醇治疗晚期乳腺癌患者,不仅可以提高临床疗效及降低肿瘤标志物水平,还可以降低不良反应发生,神经毒性副作用可控。 |
| 英文摘要: |
| 【】 Objective To investigate and analyze the effect of albumin-bound paclitaxel on the efficacy of patients with advanced breast cancer. Methods A total of 80 cases of advanced breast cancer patients who received treatment at the Dongyang Traditional Medicine Hospital between January 2019 and October 2023 were selected for the study, and they were divided into the observation group and the control group, with 40 cases in each group. Patients in the control group were treated with albumin-bound paclitaxel, and the observation group was treated with docetaxel. The level of tumor markers (carcinoembryonic antigen (CEA) and carbohydrate antigen 153 (CA153)) after treatment, efficacy (overall response rate, ORR) and incidence of adverse drug reactions of the two groups were compared. Results The levels of CEA and CA153 in observation group were lower than those in control group (P＜0.05). After treatment, the ORR of the observation group was significantly higher than that of the control group (80.0％ and 55.0％respectively, P < 0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group (P < 0.05). The difference in neurotoxicity between the two groups was statistically significant (P＜0.05), with albumin paclitaxel significantly higher at 42.5%. Conclusion The treatment of advanced breast cancer patients with albumin-bound paclitaxel not only improves clinical efficacy, but also reduces the incidence of adverse effects. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |
|
|
|